Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Biogen
Company Monitoring Page for Biogen
latest headlines for company on cafepharma
Biogen shareholders vote in Susan Langer as director despite relationship with former board member
Fierce Pharma
Mon, 06/26/23 - 08:42 pm
Tags:
Biogen
,
shareholders
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
Tags:
FDA
,
SAGE Therapeutics
,
Biogen
,
zuranolone
,
Eisai
,
Leqembi
,
Sanofi
,
AstraZeneca
,
nirsevimab
,
Iveric Bio
,
Zimura
,
Alnylam
,
Onpattro
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Fri, 06/23/23 - 10:03 am
Tags:
Biogen
,
Eisai
,
Alzheimer's disease
,
FDA
,
Leqembi
Roche drops antisense drug after seeing efficacy data, leaving Biogen, Ionis and Ultragenyx to duke it out
Fierce Biotech
Fri, 06/23/23 - 09:46 am
Tags:
Roche
,
Angelman Syndrome
,
antisense
,
Biogen
,
Ionis Pharmaceuticals
,
Ultragenyx
,
rugonersen
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Mon, 06/19/23 - 10:21 am
Tags:
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
,
Europe
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Fri, 06/16/23 - 10:01 am
Tags:
Eisai
,
Biogen
,
Alzheimer's disease
,
FDA
,
Leqembi
The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
Forbes
Wed, 06/14/23 - 06:42 pm
Tags:
Alzheimer's disease
,
drug pricing
,
Medicare
,
Biogen
,
Eisai
,
Leqembi
Biogen teams with NeuroSense to explore ALS neurofilament biomarker
BioSpace
Wed, 06/14/23 - 11:35 am
Tags:
Biogen
,
NeuroSense Therapeutics
,
ALS
,
PrimeC
Biogen Makes Changes to Board of Directors Ahead of Annual Shareholder Meeting
BioSpace
Tue, 06/13/23 - 10:44 am
Tags:
Biogen
How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial
Forbes
Mon, 06/12/23 - 10:08 am
Tags:
clinical trials
,
innovation
,
ALS
,
Parkinson's Disease
,
Biogen
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
BioPharma Dive
Sun, 06/11/23 - 11:14 pm
Tags:
Eisai
,
Biogen
,
Leqembi
,
FDA
,
Alzheimer's disease
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Tags:
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
,
South Korea
,
Asia
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 06/7/23 - 09:53 pm
Tags:
FDA
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Tags:
Alzheimer's disease
,
FDA
,
insurance
,
Leqembia
,
Biogen
,
Eisai
,
Eli Lilly
,
donanemab
After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaints
Fierce Biotech
Wed, 06/7/23 - 10:15 am
Tags:
Merck
,
Inflation Reduction Act
,
legal
,
drug pricing
,
Biogen
,
Novartis
,
Genentech
,
BIO 2023
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
Tue, 06/6/23 - 10:17 am
Tags:
FDA
,
Biogen
,
Eisai
,
Alzheimer's disease
,
Leqembi
Biogen scraps late-stage study for Parkinson’s drug
BioPharma Dive
Mon, 06/5/23 - 09:54 pm
Tags:
Biogen
,
clinical trials
,
Parkinson's Disease
,
BIIB122
PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs
Fierce Pharma
Sun, 06/4/23 - 04:15 pm
Tags:
Biogen
,
Eisai
,
Alzheimer's disease Leqembi
,
CMS
,
PhRMA
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Fri, 06/2/23 - 10:18 am
Tags:
Medicare
,
Alzheimer's disease
,
Eisai
,
Biogen
,
Leqembi
Quanterix sees a bright future for blood biomarkers
EP Vantage
Fri, 06/2/23 - 10:08 am
Tags:
Biogen
,
Quanterix
,
diagnostics
,
Qalsody
,
ALS
,
biomarkers
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
an umbrella protects you from: rain, sand, hunger
*
Fill in the blank.